Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers

Trial Profile

Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers

Completed
Phase of Trial: Phase 0

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs 18F MNI 952 (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease; Progressive supranuclear palsy
  • Focus Diagnostic use
  • Most Recent Events

    • 05 Oct 2017 Status changed from recruiting to completed.
    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top